a
a
Weather:
No weather information available
HomeHealthAlphyn Doses First Patients in CLEAR-AD1 Global Phase 2b Clinical Trial Program for Atopic Dermatitis

Alphyn Doses First Patients in CLEAR-AD1 Global Phase 2b Clinical Trial Program for Atopic Dermatitis

Zabalafin Hydrogel first topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection ANNAPOLIS, Md. and VIENNA, May 12, 2025 /PRNewswire/ — Alphyn GmbH, a clinical-stage dermatology company developing…

No comments

Sorry, the comment form is closed at this time.

Translate »